Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;30(2):111-4.
doi: 10.5001/omj.2015.24.

Rituximab leads to long remissions in patients with chronic immune thrombocytopenia

Khalid Al-Habsi  1 , Murtadha Al-Khabori  1 , Muhanna Al-Muslahi  1 , Anil Pathare  1 , Khalil Al-Farsi  1 , Mohammed Al-Huneini  1 , Sulayma Al-Lamki  1 , Salam Al-Kindi  1
Affiliations

Rituximab leads to long remissions in patients with chronic immune thrombocytopenia

Khalid Al-Habsi et al. Oman Med J. 2015 Mar.

Abstract

Objectives: To assess the response rate and duration of response in patients with chronic immune thrombocytopenia (ITP) receiving rituximab.

Methods: We retrospectively analyzed 32 consecutive patients with chronic ITP who were treated in two tertiary centers in Oman. Response assessment was based on the American Society of Hematology criteria.

Results: Nineteen patients (59%) had an initial response. However, six of the 19 patients lost their response leaving 13 patients with long-lasting remissions. The median age at diagnosis was 25 years (range 14-58). The median time from diagnosis to rituximab therapy was 21 months. The median follow-up after starting rituximab was 26 months. The overall cumulative response rate was 59% (complete response 44%, partial response 15%) and the median time to respond was 30 days with a response rate of 44% at four weeks. In all responders, the cumulative rate of loss of response was 32% with a median time to lose response of 54 months.

Conclusions: The use of rituximab in ITP achieves high response rate and long remission duration. Our study was limited by the small sample size and further larger prospective studies are recommended.

Keywords: Blood Platelets; Purpura, Thrombocytopenic, Idiopathic; Rituximab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The cumulative response rate after rituximab treatment.
Figure 2
Figure 2
The cumulative rate of loss of response after an initial response.
See this image and copyright information in PMC

References

    1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009. Mar;113(11):2386-2393. http://www.ncbi.nlm.nih.gov/pubmed/19005182. Accessed 27 May 2014. Internet. 10.1182/blood-2008-07-162503 - DOI - PubMed
    1. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. . International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010. Jan;115(2):168-186. 10.1182/blood-2009-06-225565 - DOI - PubMed
    1. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008. Jan;99(1):4-13. - PubMed
    1. Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 2003. Aug;25(8):660-664. 10.1097/00043426-200308000-00017 - DOI - PubMed
    1. Iyori H, Bessho F, Ookawa H, Konishi S, Shirahata A, Miyazaki S, et al. Japanese Study Group on childhood ITP . Intracranial hemorrhage in children with immune thrombocytopenic purpura. Japanese Study Group on childhood ITP. Ann Hematol 2000. Dec;79(12):691-695. 10.1007/s002770000219 - DOI - PubMed

LinkOut - more resources